Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …

Background Allogeneic hematopoietic stem cell transplantation (HSCT) can expose patients
to a transient but marked immunosuppression, during which viral infections are an important …

Abstract The Practice Guidelines Committee of the American Society of Transplantation and
Cellular Therapy (ASTCT) partnered with its Transpl. Infect. Dis. Special Interest Group (TID …

Virus-specific T-cells (VSTs) from third-party donors mediate short-and long-term antiviral
effects in allogeneic hematopoietic stem cell transplant (HSCT) recipients with relapsed or …

A diverse range of viruses have well-established roles as the primary driver of oncogenesis
in various haematological malignancies and solid tumours. Indeed, estimates suggest that …

Infection with adenoviruses is a common and significant complication in pediatric patients
after allogeneic hematopoietic stem cell transplantation. Treatment options with traditional …

Immunotherapy with antigen-specific T cells is a promising, targeted therapeutic option for
patients with cancer as well as for immunocompromised patients with virus infections. In this …

Over the last two decades there has been increasing interest in using antigen-specific T
cells expanded in vitro to treat hematologic malignancies. Lymphomas associated with …

Epstein-Barr virus (EBV) is a ubiquitous human tumor virus, which contributes to the
development of lymphoproliferative disease, most notably in patients with impaired …

Chimeric antigen receptor (CAR) T cell therapy has effectively complemented the treatment
of advanced relapsed and refractory hematological cancers. The remarkable achievements …